Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. Co. markets Rubraca®, which is an oral small molecule inhibitor of poly ADP-ribose polymerase for indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Co.'s product candidates include: FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein; and Lucitanib, an oral potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1 through 3.